Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

Christopher A. Yasenchak; Rodolfo Eduardo Bordoni; Dipti Patel-Donnelly; Tim Larson; Jerome H. Goldschmidt; Ralph V. Boccia; Vivian Jean M. Cline; Andres Forero-Torres; Robert Brownell Sims; Trevor Newhook; Jonathan W. Friedberg

doi:10.1200/JCO.2020.38.15_SUPPL.8032

Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

Christopher A. Yasenchak
, Rodolfo Eduardo Bordoni
, Dipti Patel-Donnelly
, Tim Larson
, Jerome H. Goldschmidt
, Ralph V. Boccia
, Vivian Jean M. Cline
, Andres Forero-Torres
, Robert Brownell Sims
, Trevor Newhook
, Jonathan W. Friedberg

Willamette University
Georgia Cancer Specialists, Marietta, GA;
Virginia Cancer Specialists, Fairfax, VA;
Minnesota Oncology/The US Oncology Network, Minneapolis, MN;
Oncology and Hematology Assoc of SW Virginia, Blacksburg, VA;
Center for Cancer and Blood Disorders, Bethesda, MD;
Texas Oncology
Seattle Genetics
University of Rochester Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.8032
State	Published - May 25 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2020.38.15_SUPPL.8032License: Unspecified

Cite this

Yasenchak, C. A., Bordoni, R. E., Patel-Donnelly, D., Larson, T., Goldschmidt, J. H., Boccia, R. V., Cline, V. J. M., Forero-Torres, A., Sims, R. B., Newhook, T., & Friedberg, J. W. (2020). Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. Journal of Clinical Oncology, 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.8032

@article{5186ec7b5b3541c59aee0494491e5278,

title = "Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.",

author = "Yasenchak, \{Christopher A.\} and Bordoni, \{Rodolfo Eduardo\} and Dipti Patel-Donnelly and Tim Larson and Goldschmidt, \{Jerome H.\} and Boccia, \{Ralph V.\} and Cline, \{Vivian Jean M.\} and Andres Forero-Torres and Sims, \{Robert Brownell\} and Trevor Newhook and Friedberg, \{Jonathan W.\}",

note = "8032 Background: Older patients with classical Hodgkin lymphoma (cHL) have poor outcomes relative to younger patients, often due to comorbidities and toxicities related to standard first-line (1L) chemotherapy (5-yr PFS: 30\%-45\% vs 75\%-80\%) (Evens 2008; Proctor 2009). Brentuximab vedotin (BV, ADCETRIS{\textregistered}), a CD30-directed antibody-drug conjugate, has robust activity in patients refractory to several lines of chemotherapy.",

year = "2020",

month = may,

day = "25",

doi = "10.1200/JCO.2020.38.15\_SUPPL.8032",

language = "American English",

volume = "38",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

AU - Yasenchak, Christopher A.

AU - Bordoni, Rodolfo Eduardo

AU - Patel-Donnelly, Dipti

AU - Larson, Tim

AU - Goldschmidt, Jerome H.

AU - Boccia, Ralph V.

AU - Cline, Vivian Jean M.

AU - Forero-Torres, Andres

AU - Sims, Robert Brownell

AU - Newhook, Trevor

AU - Friedberg, Jonathan W.

N1 - 8032 Background: Older patients with classical Hodgkin lymphoma (cHL) have poor outcomes relative to younger patients, often due to comorbidities and toxicities related to standard first-line (1L) chemotherapy (5-yr PFS: 30%-45% vs 75%-80%) (Evens 2008; Proctor 2009). Brentuximab vedotin (BV, ADCETRIS®), a CD30-directed antibody-drug conjugate, has robust activity in patients refractory to several lines of chemotherapy.

PY - 2020/5/25

Y1 - 2020/5/25

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8032

U2 - 10.1200/JCO.2020.38.15_SUPPL.8032

DO - 10.1200/JCO.2020.38.15_SUPPL.8032

M3 - Article

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

Disciplines

Access to Document

Other files and links

Cite this